CLINICAL EVALUATION OF SULBACTAM/CEFOPERAZONE IN THE PEDIATRIC INFECTIONS

Sulbactam/cefoperazone (SBT/CPZ), a fifty-fifty combination of a β-lactamase inhibitor, SBT, and an already marketed broad spectrum cephalosporin, CPZ, was evaluated for its efficacy and safety in 25 children. The diagnoses included purulent lymphadenitis, pneumonia, acute UTI, bacteremia and purule...

Full description

Saved in:
Bibliographic Details
Published in:Japanese journal of antibiotics 1984/10/25, Vol.37(10), pp.1821-1830
Main Authors: MEGURO, HIDENORI, TAJIMA, TAKESHI, NONAKA, CHIZURU, MASHIKO, JIN, FUJII, RYOCHI, ARIMASU, OSAMU
Format: Article
Language:Japanese
Subjects:
Adolescent
Age Factors
Bacterial Infections - drug therapy
Bacterial Infections - microbiology
beta-Lactamase Inhibitors
Cefoperazone - administration & dosage
Cefoperazone - adverse effects
Cefoperazone - metabolism
Child
Child, Preschool
Drug Combinations
Drug Evaluation
Female
Humans
Infant
Male
Penicillanic Acid - administration & dosage
Penicillanic Acid - adverse effects
Penicillanic Acid - metabolism
Sulbactam
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sulbactam/cefoperazone (SBT/CPZ), a fifty-fifty combination of a β-lactamase inhibitor, SBT, and an already marketed broad spectrum cephalosporin, CPZ, was evaluated for its efficacy and safety in 25 children. The diagnoses included purulent lymphadenitis, pneumonia, acute UTI, bacteremia and purulent meningitis. SBT/CPZ was effective in all the 20 cases with bacterial infections, but strains highly resistant to CPZ were not isolated in this study. The serum and cerebrospinal-fluid levels of SBT were grossly parallel with those of CPZ, and the half-life of the serum SBT was 0.754 hour. Although severe adverse reactions were not encountered with SBT/CPZ therapy, loose stools in 20% and diarrhea in 16% of the cases were observed.
ISSN:0368-2781
2186-5477
DOI:10.11553/antibiotics1968b.37.1821